HCG: The LH Analog and Its Role in Restoration Protocols

Human chorionic gonadotropin shares a subunit with LH and activates the same receptor on Leydig cells, which is why HCG for men functions as an LH analog: it can hold up testicular function when the axis's own signal is reduced.

This article describes mechanism and general clinical context. It does not describe protocols, doses, or schedules of any kind. Any intervention on the reproductive axis is a matter for an endocrinologist.

Structure: why it behaves like LH

The gonadotropins (LH, FSH, TSH, and HCG) are glycoproteins built from two subunits:

• An alpha subunit, practically identical across all four.
• A beta subunit, which determines specificity.

The beta subunit of HCG has very high homology with the one in LH. That similarity lets it bind the same receptor, the LH/CG receptor, and activate it.

One difference matters here: the beta subunit of HCG carries a C-terminal extension with carbohydrate residues that prolongs its half-life considerably compared with LH. A molecule that does the same job but lasts far longer.

Leydig cells and the testicular response

In the testis, LH acts on the Leydig cells, which produce testosterone. FSH acts on the Sertoli cells, involved in supporting spermatogenesis.

By activating the LH receptor, HCG maintains testosterone production inside the testis, the so-called intratesticular testosterone, which reaches concentrations far above circulating levels and is required for spermatogenesis.

That distinction between circulating and intratesticular testosterone is the reason the compound is used in certain clinical contexts: supplying testosterone from outside raises the circulating level but not the intratesticular one, and the latter depends on the LH signal.

Acting low in the axis versus acting high

This is the comparison that gives the whole cluster its shape.

As the pillar on the HPG axis explains, the circuit has three levels with feedback. HCG for men works as an LH analog at the final step: it replaces the LH signal at the gonad.

What that achieves: it maintains the gonadal response even when the body's own signal is reduced.

What it does not achieve, and this is the central point: it does not restore the hypothalamic signal. The hypothalamus still fails to produce GnRH in a normal pattern, and the pituitary still fails to produce its own LH and FSH. The upper circuit stays just as quiet.

That is the difference with kisspeptin, which acts above the hypothalamus and stimulates the circuit at its natural entry point.

Approved clinical use and off-label use

HCG is a medication with approved indications from regulatory agencies, among them assisted reproduction settings, certain hypogonadotropic hypogonadisms, and cryptorchidism in pediatric patients.

There is also widespread off-label use in contexts of axis suppression. Three points on that:

Off-label use is not illegal, nor necessarily inappropriate, when the person doing it is a professional with clinical judgment and responsibility for the case.

It is different, though, from self-administration with no evaluation and no follow-up.

This article does not describe those protocols. Not to dodge the question, but because these are clinical decisions that depend on the individual situation, require follow-up lab work, and cannot be generalized in a text.

Handling and stability considerations

HCG comes lyophilized and requires reconstitution. Two particulars:

It is a glycoprotein, not a short peptide. It is a larger, more complex molecule with attached carbohydrates, and it is more sensitive to temperature and agitation than a small peptide. Careful reconstitution technique matters more here than with other compounds.

Once reconstituted it requires refrigeration, and its stability window is more limited. The general rules are in the cold chain guide, and the technique, in the reconstitution guide.

HCG also does have a real international unit of biological activity, unlike most peptides, where "units" means syringe volume. It is one of the few exceptions to what the conversion article explains.

Batch analytical data is on its product page, and the HRT compounds, in their section.

What it does not do

A necessary section, because expectations around this compound tend to run well past its mechanism:

It does not restore the hypothalamic or pituitary signal. It replaces a signal; it does not switch the upper circuit back on.

It does not substitute for FSH. It acts on the LH receptor. Sertoli cell function depends on a different signal.

It is not a fertility treatment on its own. In clinical fertility settings it is used within protocols that assess the axis as a whole.

It does not avoid negative feedback. By maintaining testosterone production, it contributes to the signal that brakes the upper axis.

What the evidence does not settle

Off-label protocols are far less well characterized than approved uses, and their evidence comes largely from clinical practice rather than from trials.

Recovery of the axis after suppression is variable and imperfectly predictable.

Individual response depends on duration of suppression, age, and baseline status, with no reliable model to anticipate it.

This content is strictly educational and does not constitute medical advice, diagnosis or a therapeutic recommendation. The compounds mentioned are research products (Research Use Only) and are not approved by INVIMA, FDA, EMA or ANSM for therapeutic use in humans. Any health-related decision should be made with a licensed medical professional.